ProMetic Life Sciences Inc. (PLI) 2014年年度报告「TSX」.pdf

1、Growing for life2014 ANNUAL REPORTExecutive Summary 1Significant Events 2Message to Shareholders 4Plasma-derived and Small Molecule Therapeutics 6MD&A 12Financial Statements 37Management Team andBoard of Directors 79Corporate Information 80Table of contentsPROMETIC LIFE SCIENCES INC.1Historically kn

2、own for its world-class expertise in bioseparation,ProMetic is continuing to transition into a vertically integrated biopharmaceutical corporation with a rapidly growing pipeline of drug candidates originating from two development platforms.1-PROTEIN TECHNOLOGIESBIOSEPARATION TECHNOLOGIESThe biosepa

3、ration technologies enable the capture of multiple,targeted proteins directly from source products and provide for a highly efficient and cost-effective process.In order to assure high quality standards required for protein pharmaceuticals,ProMetic has employed its affinity technologies to create a

4、range of bioseparation products that assist in improving the purification of therapeutic proteins and antibodies.The Corporations proprietary purification adsorbents and manufacturing processes for biological products are used by more than 30 companies in the pharmaceutical,biotechnology and medical

5、 industries,where ProMetics clients employ this technology to purify proteins,remove impurities and pathogens,reduce manufacturing costs,and increase the yield of therapeutic products.PLASMA-DERIVED BIOPHARMACEUTICALSAt the heart of our proprietary manufacturing process resides our bioseparation tec

6、hnologies and products,such as our affinity resins.These technologies and related know-how enable the capture of multiple targeted proteins and provide for a highly efficient and cost-effective plasma purification process.More than a decade ago,ProMetic,in collaboration with the American Red Cross,s